Ocriplasmin (Jetrea, ThromboGenics) may achieve lower macular hole closure rates than in trials, new British and Irish data suggests. Also, “the incidence of adverse events was greater than previously reported,” wrote RJ Haynes of Bristol Eye Hospital in Bristol, United Kingdom, and colleagues in the journal Eye.
Analyzing data from the European Eye Study, Gareth J. McKay, PhD, of Queen’s University in Belfast, United Kingdom, and colleagues in 7 countries in Europe found no meaningful association between serum 25-hydroxy vitamin D (25(OH)D) and AMD. They published the finding in Ophthalmology.
Millions of adults around the world run the risk of losing their eyesight because of inattention to complications of diabetes, according to a team of international researchers. “A quarter of people with diabetes surveyed are not discussing eye complications with their health care professional, with many presenting when vision problems have already occurred,” the report said.
Optical services chains in the United Kingdom are misleading customers about filters to screen out blue light from electronic devices, according to the BBC. Boots Opticians and Vision Express both claim that the filters protect against retinal damage despite a lack of evidence, the news service said in a recent press release.
Adalimumab (Humira, AbbVie), an immunosuppressive biologic therapy, improves the symptoms of noninfectious active uveitis, but causes some adverse events and does not cure the disease, researchers say.
The US Food and Drug Administration (FDA) is expediting its review of a new potential treatment for giant cell arteritis, a rare inflammatory disease that can cause permanent vision loss, Roche has announced.